Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635293 | 1.00 | ELANE (0.36) | ELANEBIRC2NAMPTABHD6MMP2 | |
| SCHEMBL12726041 | 0.89 | ELANE (0.46) | ELANEBIRC2NAMPTDDB1CRBN | |
| SCHEMBL8122985 | 0.87 | NAMPT (0.35) | ELANENAMPTABHD6DDB1CRBN | |
| Hydrochloric Acid SCHEMBL1635341 | 0.86 | NAMPT (0.35) | ELANENAMPTABHD6DDB1CRBN | |
| Hydrochloric Acid SCHEMBL1635343 | 0.86 | NAMPT (0.35) | ELANENAMPTABHD6DDB1CRBN | |
| SCHEMBL1636066 | 0.83 | DDB1 (0.36) | ELANENAMPTABHD6DDB1CRBN | |
| SCHEMBL1636070 | 0.83 | DDB1 (0.36) | ELANENAMPTABHD6DDB1CRBN | |
| SCHEMBL1634817 | 0.82 | DDB1 (0.42) | NAMPTABHD6DDB1CRBN | |
| SCHEMBL3645554 | 0.82 | DDB1 (0.42) | NAMPTABHD6DDB1CRBN | |
| SCHEMBL1634816 | 0.82 | DDB1 (0.42) | NAMPTABHD6DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2185524-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2008141227-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | ELANE 365/4885BIRC2 694/4885NAMPT 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.